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Abstract: Patients are considered to be at high risk of cardiovascular events if they have diabetes, 
chronic kidney disease, stroke, established coronary artery disease, or a coronary artery disease 
equivalent. Blood pressure-lowering therapy has been shown to reduce cardiovascular events 
in these patients significantly. Identification of high-risk patients by global risk evaluation is 
recommended for every hypertensive patient. Treatment of hypertension in high-risk patients 
with an angiotensin-converting enzyme inhibitor or an angiotensin receptor antagonist, with 
or without addition of a dihydropyridine calcium channel antagonist, is a reasonable approach 
based on current clinical trials.
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Introduction
Cardiovascular disease is an important cause of death worldwide. Hypertension is 
one of the major risk factors and is correlated with a risk of stroke, coronary artery 
disease, peripheral vascular disease, heart failure, and renal disease.1,2 Together with 
other risk factors, including diabetes mellitus, dyslipidemia, smoking, and obesity, 
hypertension significantly contributes to the global cardiovascular burden of morbidity 
and mortality, as well as increasing individual absolute cardiovascular risk.3
Identifying and treating risk factors in patients at high risk of cardiovascular events 
can significantly reduce the risk.4 Patients are considered to be at high risk if they 
have diabetes, chronic kidney disease, stroke, established coronary artery disease, 
or a coronary artery disease equivalent, including carotid artery disease, peripheral 
arterial disease, and abdominal aneurysm.1 Blood pressure-lowering therapy has been 
shown to reduce cardiovascular events in these patients significantly.5 Successful 
prevention of cardiovascular events in high-risk patients requires identification of 
patients at risk and comprehensive risk factor management, including treatment of 
hypertension.
Identification of high-risk patients
The risk of a cardiovascular event increases dramatically when a hypertensive patient 
has vascular disease, including coronary artery disease, cerebrovascular disease, 
and peripheral vascular disease.1,4,6 In patients with diabetes mellitus, up to 65% 
of deaths are due to coronary artery disease and/or stroke, and diabetes mellitus 
has been   considered as a coronary disease equivalent.4,7 Clustering of risk factors 
increases the risk of cardiovascular events. The Multiple Risk Factor Intervention Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Trial demonstrated that cardiovascular mortality increases 
significantly when the number of risk factors accumulates.8 
The presence of left ventricular hypertrophy has also been 
shown to increase the risk of cardiovascular events in hyper-
tension significantly.9
Total cardiovascular risk assessment is recommended 
during the initial evaluation of all hypertensive patients.10 
Factors influencing prognosis include blood pressure 
levels, other cardiovascular risk factors, diabetes mellitus 
or metabolic syndrome, subclinical organ damage, and 
established vascular or renal disease.10 A summary of high-
risk conditions is listed in Table 1.
Major trials in high-risk patients
Many clinical trials have investigated the effects of reducing 
cardiovascular risk in the treatment of hypertension. These 
large, randomized, controlled trials provide clinical evidence 
and have implications for the treatment of hypertension in 
high-risk patients (Table 2).11–17
The Heart Outcomes Prevention Evaluation study 
demonstrated that the angiotensin-converting enzyme 
inhibitor, ramipril, could significantly reduce primary 
endpoints (myocardial infarction, stroke, cardiovascular 
death) in high-risk patients.11 The Losartan Intervention 
For Endpoint reduction in hypertension study compared 
the angiotensin receptor antagonist, losartan, with the 
beta-blocker, atenolol, in patients with left ventricular 
hypertrophy. The degree of left ventricular hypertrophy 
regression and primary endpoints (myocardial infarction, 
stroke, cardiovascular death) were significantly improved in 
the losartan group than in the atenolol group.12 The Anglo-
Scandinavian Cardiac Outcome Trial – Blood Pressure 
Lowering Arm compared amlodipine-based (with or without 
an angiotensin-converting enzyme inhibitor) and atenolol-
based (with or without a thiazide diuretic) treatment in 
hypertensive patients with three or more study-specified 
risk factors. This study did not show any differences in the 
primary endpoints (nonfatal myocardial infarction and fatal 
coronary artery disease), but did show a significantly reduced 
number of overall cardiovascular events (hazard ratio [HR] 
0.84, 95% confidence interval 0.78–0.90, P , 0.0001) in the 
amlodipine-based treatment group.13 The Action in Diabetes 
and Vascular Disease: Preterax and Diamicron-Controlled 
Evaluation Trial included patients with Type 2 diabetes 
mellitus and assessed the effects of the combination of the 
angiotensin-converting enzyme inhibitor, perindopril, and 
a diuretic, indapamide, on vascular events. The primary 
endpoints (macrovascular and microvascular events) were 
significantly reduced in the active treatment group (relative 
risk reduction 9%, P = 0.04). All cause mortality (HR 0.86, 
P = 0.03) and coronary events (HR 0.86, P = 0.02) were 
also significantly reduced in the active treatment group.14 
The Ongoing Telmisartan Alone and in Combination With 
Ramipril Global Endpoint Trial (ONTARGET) study 
involved high-risk patients with coronary, peripheral arterial, 
or cerebrovascular disease, and diabetic patients with target 
organ damage. The patients were randomized into ramipril, 
telmisartan, and ramipril + telmisartan groups. The primary 
endpoints (the composite of cardiovascular death, myocardial 
infarction, stroke, or hospitalization for heart failure) were 
similar in these groups. However, more hypotension and 
renal dysfunction were noted in the combination group.15 
The Telmisartan Randomized Assessment Study in ACE 
Intolerant Subjects With Cardiovascular Disease study 
included patients who were screened for the ONTARGET 
study but were unable to tolerate angiotensin-converting 
enzyme inhibitors. The primary composite outcome was 
the same as for the ONTARGET study, and occurred in 
15.7% of the telmisartan patients and 17.0% of the placebo 
patients (P = 0.22). However, the telmisartan group 
had significantly lower composite secondary outcomes 
(P = 0.048).16 The Avoiding Cardiovascular Events Through 
Combination Therapy in Patients Living With Systolic 
Hypertension study tested whether treatment with the 
combination of an angiotensin-converting enzyme inhibitor 
and a dihydropyridine calcium channel blocker was more 
effective than combination with a thiazide in cardiovascular 
event reduction. The primary outcome (the composite of death 
from cardiovascular causes, nonfatal myocardial infarction, 
nonfatal stroke, hospitalization for angina, resuscitation after 
sudden cardiac arrest, and coronary revascularization) was 
significantly lower in the benazepril + amlodipine group than 
in the benazepril + hydrochlorothiazide group.17
Table 1 High risk conditions in hypertension*
Systolic blood pressure $180 mmHg and/or diastolic 
blood pressure $110 mmHg
Diabetes mellitus
Metabolic syndrome
Three or more cardiovascular risk factors
One or more manifestations of subclinical organ damage, eg, left 
ventricular hypertrophy
established coronary artery disease
established cerebrovascular disease
established peripheral vascular disease
established chronic kidney disease
Note: *Adapted from the 2007 european Society of Hypertension and the european 
Society of Cardiology guidelines for the treatment of arterial hypertension.10Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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From the results of these trials, it is reasonable to 
recommend using an angiotensin-converting enzyme 
inhibitor or angiotensin receptor blocker for the treatment 
of hypertension in high-risk patients. The combination of 
an angiotensin-converting enzyme inhibitor or angiotensin 
receptor blocker with a dihydropyridine calcium channel 
blocker was also shown to be beneficial in the treatment 
of high-risk patients. However, the combination of an 
angiotensin-converting enzyme inhibitor with an angiotensin 
receptor blocker should only be used sparingly and very 
carefully in patients at high risk based on the currently 
available evidence.18
Level and speed of blood pressure-
lowering in high-risk patients
Most of the hypertension treatment guidelines recommend 
a blood pressure target of ,130/80 mmHg for high-risk 
patients.1,9,10 Critical analyses of the results of available trials 
show that the evidence is scanty for this recommendation.19 
Most of the clinical trials did not reach this blood 
pressure target when treating-high risk patients, and the 
recommendation is based more on assumptions than on 
hard evidence.19 The Action to Control Cardiovascular Risk 
in Diabetes blood pressure trial demonstrated that targeting 
a systolic blood pressure of ,120 mmHg as compared 
with ,140 mmHg did not reduce cardiovascular risk in 
high-risk diabetes patients.20 Further studies are needed to 
confirm the ideal blood pressure target for high-risk patients. 
Nonetheless, all observations indicate that aiming at a lower 
blood pressure target of 130 mmHg does not increase risk 
and is well tolerated.19 Therefore, it is acceptable currently 
to advise targeting a systolic blood pressure of 130 mmHg 
in clinical practice.
There is no doubt that antihypertensive medication 
should be initiated immediately in high or very high-risk 
hypertensive patients.10 The concept of “sooner is better” 
is important for high-risk patients based on the Valsartan 
Antihypertensive Long-term Use Evaluation (VALUE) 
trial.21 The VALUE trial showed that a greater blood pressure 
reduction in the first six months in the amlodipine group was 
associated with a lower cardiovascular event rate than in the 
valsartan group.21
Role of direct renin inhibitors  
in high-risk patients
The direct renin inhibitor, aliskiren, has recently been 
developed for the treatment of hypertension. Based on the 
successful results of previous studies regarding the protective Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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effects of blocking the renin-angiotensin-aldosterone system 
by angiotensin-converting enzyme inhibitors or angiotensin-
receptor blockers in high-risk patients, direct renin inhibitors 
have attracted interest due to their protective effects in 
high-risk patients. Direct renin inhibitors block the renin-
angiotensin-aldosterone system at its point of origin, and 
also decrease plasma renin activity by blocking renin or 
prorenin receptors and eliminating the adverse effects of 
renin or prorenin receptor activation.22 Some studies of organ 
protective effects have shown comparative or even better 
results with angiotensin-converting enzyme inhibitors 
or angiotensin receptor blockers when a direct renin inhibitor 
was used as monotherapy or in combination with other 
renin-angiotensin-aldosterone system inhibitors.23 The organ 
protective effect of direct renin inhibitors has been shown to 
be more pronounced for the kidney.24 Direct renin inhibitors 
showed a good and rapid blood pressure-lowering response 
when used in combination with a calcium channel antagonist 
in a recently published hypertension study.25 Used alone or 
in combination, direct renin inhibitors have great potential in 
the treatment of hypertension in high-risk patients. However, 
results of large randomized controlled studies for the major 
cardiovascular endpoints are needed to define their role in 
high-risk patients.
Conclusion
Treatment of hypertension in high-risk patients can 
reduce cardiovascular events. Identification of high-risk 
patients by global risk evaluation is recommended for 
every hypertensive patient. Treatment of hypertension in 
high-risk patients with an angiotensin-converting enzyme 
inhibitor or an angiotensin receptor antagonist, with or 
without addition of a dihydropyridine calcium channel 
blocker, is a reasonable approach based on current clinical 
trial evidence.
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